SEC Comment Letter 0000000000-23-011670 to PSYENCE BIOMEDICAL LTD. (PBM)
PSYENCE BIOMEDICAL LTD.
Date: Oct. 25, 2023 · CIK: 0001985062 · Accession: 0000000000-23-011670
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273553
Letter
United States securities and exchange commission logo October 25, 2023 Dr. Neil Maresky Chief Executive Officer Psyence Biomedical Ltd. 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 Re:Psyence Biomedical Ltd. Amendment No. 2 to Registration Statement on Form F-4 Filed October 16, 2023 File No. 333-273553 Dear Dr. Neil Maresky: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe this comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our October 4, 2023 letter. Amendment No. 2 to Registration Statement on Form F-4 Questions and Answers about the Business Combination Who is Psyence?, page 8 1.We note your response to prior comment 2 and re-issue in part. Please revise the Q&A to remove citations to clinical data and trials of PEX010 from trials that are not conducted or sponsored by Psyence. Please contact Li Xiao at 202-551-4391 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Please contact Jimmy McNamara at 202-551-7349 or Alan Campbell at 202-551-4224 with any other questions.
FirstName LastNameDr. Neil Maresky Comapany NamePsyence Biomedical Ltd. October 25, 2023 Page 2 FirstName LastName Dr. Neil Maresky Psyence Biomedical Ltd. October 25, 2023 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ari Edelman
Show Raw Text
United States securities and exchange commission logo
October 25, 2023
Dr. Neil Maresky
Chief Executive Officer
Psyence Biomedical Ltd.
121 Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1
Re:Psyence Biomedical Ltd.
Amendment No. 2 to Registration Statement on Form F-4
Filed October 16, 2023
File No. 333-273553
Dear Dr. Neil Maresky:
We have reviewed your amended registration statement and have the following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe this comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments. Unless we note otherwise,
any references to prior comments are to comments in our October 4, 2023 letter.
Amendment No. 2 to Registration Statement on Form F-4
Questions and Answers about the Business Combination
Who is Psyence?, page 8
1.We note your response to prior comment 2 and re-issue in part. Please revise the Q&A to
remove citations to clinical data and trials of PEX010 from trials that are not conducted or
sponsored by Psyence.
Please contact Li Xiao at 202-551-4391 or Kevin Vaughn at 202-551-3494 if you have
questions regarding comments on the financial statements and related matters. Please contact
Jimmy McNamara at 202-551-7349 or Alan Campbell at 202-551-4224 with any other questions.
FirstName LastNameDr. Neil Maresky
Comapany NamePsyence Biomedical Ltd.
October 25, 2023 Page 2
FirstName LastName
Dr. Neil Maresky
Psyence Biomedical Ltd.
October 25, 2023
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ari Edelman